(Q89217688)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

review article

1 reference

title

Post-transplant lymphoproliferative disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

lymphoproliferative disorders

1 April 2020

main subject

1 reference

2

Angela C Webster

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

author name string

Vikas R Dharnidharka

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Olivia M Martinez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Jutta K Preiksaitis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Veronique Leblond

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Sylvain Choquet

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

publication date

28 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Disease Primers

1 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

page(s)

15088

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

Post-transplant lymphoproliferative disease

1 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Post-transplant lymphoproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-Barr virus infection and posttransplant lymphoproliferative disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Reticulum Cell Sarcoma after Renal Homotransplantation and Azathioprine and Prednisone Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Lymphomas after solid organ transplantation: a collaborative transplant study report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Lymphoproliferative disease after renal transplantation in Australia and New Zealand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Post-transplant Lymphoproliferative Disorders: Determination of Donor/Recipient Origin in a Large Cohort of Kidney Recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Seronegative hepatitis C virus infection in patients with lymphoproliferative disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Complete absence of KSHV/HHV-8 in posttransplant lymphoproliferative disorders: an immunohistochemical and molecular study of 52 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

EBV persistence in memory B cells in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Detection of clonal EBV episomes in lymphoproliferations as a diagnostic tool

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Integrated and episomal forms of Epstein-Barr virus (EBV) in EBV associated disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Visualization of episomal and integrated Epstein-Barr virus DNA by fiber fluorescence in situ hybridization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-Barr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-Barr virus: evasive maneuvers in the development of PTLD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The EBNA3 family of Epstein-Barr virus nuclear proteins associates with the USP46/USP12 deubiquitination complexes to regulate lymphoblastoid cell line growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The immunology of Epstein-Barr virus-induced disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

EBV-specific CD8+ T cells from asymptomatic pediatric thoracic transplant patients carrying chronic high EBV loads display contrasting features: activated phenotype and exhausted function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case-control study in a renal transplant cohort.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

INTERLEUKIN-10 AND POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER KIDNEY TRANSPLANTATION1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-Barr virus modulates host cell microRNA-194 to promote IL-10 production and B lymphoma cell survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Interleukin-6 production in posttransplant lymphoproliferative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

A distinct subpopulation of human NK cells restricts B cell transformation by EBV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Role for early-differentiated natural killer cells in infectious mononucleosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The NPC derived C15 LMP1 protein confers enhanced activation of NF-kappa B and induction of the EGFR in epithelial cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

EBNA-1 sequence variation in Danish and Chinese EBV-associated tumours: evidence for geographical polymorphism but not for tumour-specific subtype restriction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The viral and cellular microRNA targetome in lymphoblastoid cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Identification of virus-encoded microRNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

MicroRNAs as mediators of viral evasion of the immune system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

EBV microRNA BART 18-5p targets MAP3K2 to facilitate persistence in vivo by inhibiting viral replication in B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

An epigenetic view of B-cell disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

(18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Interlaboratory comparison of epstein-barr virus viral load assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein-Barr virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Prompt versus preemptive intervention for EBV lymphoproliferative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-Barr virus, rapamycin, and host immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Inhibition of mTORC1 inhibits lytic replication of Epstein-Barr virus in a cell-type specific manner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Monitoring infection with Epstein-Barr virus among seromismatch adult renal transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

T lymphocytes targeting native receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Immunotherapy for EBV-associated malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

(Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein-Barr virus transmission during transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Epstein-barr virus vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Effective clearance of methotrexate using high-flux hemodialysis membranes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Early onset, EBV(-) PTLD in pediatric liver-small bowel transplantation recipients: a spectrum of plasma cell neoplasms with favorable prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Donor T cells to treat EBV-associated lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Improved survival with recent Post-Transplant Lymphoproliferative Disorder (PTLD) in children with kidney transplants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Preemptive Therapy of EBV-Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell Transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Hyperexpression of Foxp3 and IDO during acute rejection of islet allografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Successful renal retransplantation after post-transplant lymphoproliferative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

New approaches to treating B-cell cancers induced by Epstein-Barr virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Resveratrol prevents EBV transformation and inhibits the outgrowth of EBV-immortalized human B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Targeted activation of human Vγ9Vδ2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

The Seville expert workshop for progress in posttransplant lymphoproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Characteristic Pattern of Chromosomal Imbalances in Posttransplantation Lymphoproliferative Disorders: Correlation with Histopathological Subcategories and EBV Status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

HLA class I associations with EBV+ post-transplant lymphoproliferative disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Early onset post-transplant lymphoproliferative disease is associated with allograft localization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.88

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRDP.2015.88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189056%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

1 reference